Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Fludzoparib" and Anti-angiogenic 1

Interventions

pembrolizumab 221Carboplatin 214Cisplatin 202Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 113Cyclophosphamide 101Pemetrexed 100Dexamethasone 100Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 92Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 67durvalumab 65Lenalidomide 64atezolizumab 61Radiation 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × fluzoparib × 1 year × Clear all
NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
200 enrolled
Breast

Fludzoparib" and Anti-angiogenic

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
252 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡